BiotechTube

Carboplatin + Mirvetuximab Soravtansine + Bevacizumab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epithelial Ovarian Cancer

Conditions

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant

Trial Timeline

Nov 21, 2025 → Feb 1, 2030

NCT ID
NCT06890338

About Carboplatin + Mirvetuximab Soravtansine + Bevacizumab

Carboplatin + Mirvetuximab Soravtansine + Bevacizumab is a phase 2 stage product being developed by AbbVie for Epithelial Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06890338. Target conditions include Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06890338Phase 2Recruiting

Competing Products

20 competing products in Epithelial Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
LY2228820 + Carboplatin + Placebo + GemcitabineEli LillyPhase 1/2
41
gemcitabine + carboplatin + paclitaxelEli LillyPhase 2
52
PemetrexedEli LillyPhase 2
52
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
52
Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
77
Mirvetuximab SoravtansineAbbViePhase 2
52
AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + TopotecanAstraZenecaPhase 3
77
AvelumabAstraZenecaPhase 2
52
Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3
77
Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weeklyAstraZenecaPhase 2
52
Olaparib + BevacizumabAstraZenecaApproved
85
Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™MerckPhase 3
77
PembrolizumabMerckPhase 2
52
MK-1775 and carboplatinMerckPhase 2
52
GardasilMerckPhase 1
33
NG-350A plus PembrolizumabMerckPhase 1
33
Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)MerckPhase 3
77
V501MerckPhase 3
77
9-valent HPV vaccinationMerckPhase 2
52
Human Papillomavirus vaccineMerckPhase 2
52

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85